New molecular entity: Vesicare, Yamanouchi/GlaxoSmithKline solifenacin.
D000284:Administration, Oral; D017277:Drug Approval; D004347:Drug Interactions; D006801:Humans; D011812:Quinuclidines / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D001745:Urinary Bladder Diseases / Q000188:drug therapy*
D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate